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Abstract
Introduction: Cardiovascular disease (CVD) is the leading cause of death worldwide: no other reason causes as many 
deaths a year as CVD. An estimated 17.9 million people died of CVD in 2016, accounting for 31% of all deaths in the 
world. People with CVD or at high risk for these diseases (due to one or more risk factors, such as high blood pressure, 
diabetes, hyperlipidemia, or an already developed disease) need early detection and assistance through counseling and, 
if necessary, taking medication.
Ways to find new targets for the correction of endothelium-associated pathology: The basis of the modern therapy 
for arterial hypertension and other cardiovascular diseases is the postulate of the need to correct endothelial dysfunc-
tion as an indication of the adequacy of antihypertensive and other types of treatment. Lowering blood pressure (BP) 
without normalizing endothelial function cannot be considered a successfully resolved clinical task. Currently, there are 
no drugs for specific pharmacological correction of endothelial dysfunction in cardiovascular diseases, and the search 
for new targets for pharmacological correction of endothelial dysfunction is one of the main tasks of pharmacology.
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Introduction
Cardiovascular diseases continue to be the leading cause 
of death and disability, which necessitates the need for an 
in-depth study of the pathogenesis and the development 
of treatment and prevention measures.
In the modern world, especially in developed coun-
tries, arterial hypertension (AH) is one of the main fac-
tors that increase disability and mortality due to such 
severe complications as myocardial infarction, heart fail-
ure and stroke. In Russia, the prevalence of hypertension 
among the adult population exceeds 30%, which makes 
the country a leader in Europe in mortality from strokes 
and coronary artery disease. One of the main causes of 
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hypertension is endothelial dysfunction (ED), in the first 
place – impaired relaxation properties of the endothelium.
The basis of modern therapy of arterial hypertension 
and other cardiovascular diseases is the postulate of the 
need to correct endothelial dysfunction as an indicator of 
the adequacy of antihypertensive and other types of treat-
ment. In fact, this means that a decrease in BP without 
normalizing endothelial function cannot be considered a 
successfully solved clinical task (Kyoung and Woo 2012).
“ADMA-eNOS” as a pharmacological target is of un-
doubted interest and has been the object of pharmacolog-
ical studies (Gumanova et al. 2007, Jiang et al. 2016, Ko-
rokina et al. 2009, Korokin et al. 2011, Kostina et al. 2016, 
Pokrovskii et al. 2006, Pokrovskii et al. 2008, Pokrovskii 
et al. 2011, Pokrovskii et al. 2012, Pokrovskaya et al. 
2007, Voronkov et al. 2008, Tsepeleva et al. 2011, Tyu-
renkov and Voronkov 2008, Tyurenkov et al 2009, Sha-
belnikova et al. 2015, Shakhno et al. 2017, Yakushev 
and Pokrovskii 2016). The studies have revealed the role 
of methylated derivatives of L-arginine – monomethy-
larginine (L-NMMA) and asymmetric dimethylarginine 
(ADMA) as endogenous inhibitors of endothelial NO 
synthase (eNOS).
Earlier studies showed that preventing the accumula-
tion and overcoming of inhibition of eNOS by an already 
established ADMA can be one of the ways to pharma-
cologically correct endothelial dysfunction. Endothelium 
protective properties realized by reducing the inhibito-
ry effect of ADMA on eNOS agents, such as L-arginine 
(Pokrovskii et al. 2008), tetrahydrobiopterin, non-selec-
tive arginase inhibitor L-norvaline, and selective arginase 
II inhibitors (Yakushev and Pokrovskii 2016), etc., were 
experimentally confirmed.
It has also been established that systemic inflammatory 
diseases, by increasing the level of oxidative stress, lead 
to the formation of oxidized forms of high-density circu-
lating lipoprotein. The accumulation of lipid peroxidation 
products may adversely affect the function of endothelial 
cells, but the basic mechanisms of this state, as well as 
the possibilities for its correction, remain unclear (Pérez 
et al. 2019).
Along with the accumulation of knowledge about the 
pathways of metabolic disorders of nitric oxide, the meth-
ods for assessing endothelial dysfunction also change. 
Numerous in vivo or in vitro, as well as invasive or non-in-
vasive methods are used to study endothelial function. A 
number of methods widely used in clinical studies cannot 
be used for diagnostic purposes because of their invasive-
ness, high cost, and complex standardization. A number 
of authors propose further research and investment in this 
area to make these methods applicable in clinical practice 
and, therefore, to minimize the public health problems as-
sociated with cardiovascular diseases by early diagnosis 
of endothelial dysfunction and early correction of nitric 
oxide metabolism (Steppan et al. 2013).
However, currently there are no drugs for specific 
pharmacological correction of the metabolic pathway 
L-arginine–eNOS–nitric oxide, whose disorders are a uni-
versal and fundamental trigger mechanism for initiating a 
cascade of metabolic disorders leading to arterial hyper-
tension and other diseases of the cardiovascular system.
Methods to improve and restore endothelial dysfunc-
tion in various pathological conditions are being inten-
sively studied. The data from clinical studies of drugs that 
improve endothelial dysfunction are shown in Table 1.
This article is aimed at making the case for possible 
ways to search for new targets for the pharmacological 
correction of endothelial dysfunction.
The role of NOX1 and NOX2 
oxidases in the pharmacological 
correction of endothelial 
dysfunction
The study of endothelium-dependent vasodilation began 
with the observation that the removal of endothelial cells 
from isolated arteries prevented the vasodilatory response 
to the introduction of acetylcholine. Various vasoactive 
substances, such as ligands of the G-protein-conjugated 
receptors, exhibit a similar inducing effect on vasodilati-
on. Endothelium-dependent vasodilation is caused by the 
release of prostacyclin PGI2 and nitrogen monoxide (NO) 
or endothelial hyperpolarization factors (for example, 
H2O2) (Kvietys and Granger 2012). Dilation of isolated 
arteries caused by agonists or the bloodstream is blocked 
by catalase. The enzymatic destruction of glycocalyx, li-
ning the surface of endothelial cells, significantly weakens 
the bloodstream-induced shear vasodilation (Kvietys and 
Granger 2012). Thus, the pharmacological stabilization of 
the microfilament / microtubule network of the endotheli-
al cytoskeleton can contribute to vasodilation induced by 
the bloodstream.
NADPH oxidases (NOX) are enzymes that produce 
reactive oxygen species (ROS) and are involved in the 
pathogenesis of a number of endothelium-associated dis-
eases, such as hypertension and stroke (Drummond and 
Sobey 2015).
An interesting fact is that studies have shown a de-
crease in the level of NO and an increase in the activity 
of arginase under the action of NOX2, which directly in-
dicates the participation of NOX2 in the pathogenesis of 
endothelial dysfunction. Inhibition of NOX2 activity in 
endothelial cells in mice significantly prevents premature 
aging of endotheliocytes by limiting an increase in ex-
pression and arginase activity (Rojas et al. 2017).
The main source of reactive oxygen species (ROS) 
in vascular oxidative stress, which is one of the main 
causes of cardiovascular diseases, is NOX1 and NOX2 
oxidases (Drummond et al. 2011). These NADPH•H ox-
idase isoforms are expressed by endothelial cells, and a 
balanced decrease in their activity with the help of se-
lective inhibitors can be a rational approach to the ther-
apy, including that of endothelial dysfunction. Vessel 
walls are exposed to direct destruction under the action 
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of excess ROS, which trigger a number of redox-sensi-
tive transcriptional pathways (Drummond et al. 2011). 
Low-density lipoproteins (LDL) are trapped and ox-
idized in the vascular endothelium, and the oxidized 
form of LDL causes further oxidative stress in endothe-
lial cells, smooth muscle cells, and foamy cells, which 
aggravates atherogenesis. ROSs produced in the vessel 
wall are highly reactive particles and do not force stable 
by-products into the bloodstream, which complicates the 
diagnosis of atherogenesis (Lee et al. 2012). Studies on 
the role of NADPH-H oxidases in endothelial homeo-
stasis provide strong evidence that pharmacological 
inhibitors of this enzyme can be used as agents for the 
treatment of oxidative stress and vascular pathologies 
associated with it. Some inhibitors with an established 
NADPH-oxidase inhibitory activity are presented in Ta-
ble 2 (Drummond et al. 2011).
Recently, a group of scientists developed and synthe-
sized new photoactivatable analogs of NADPH. These 
compounds have one or two carboxymethyl groups at 
the 2’- and / and 3’-positions of the ribose in the aden-
osine fragment instead of the 2’-phosphate group and 
differ in nature by the electron donor in their photoacti-
vatable chromophore (replacing the nicotinamide frag-
ment). The dependence of eNOS on the formation of 
photoinduced NO was blocked using two NOS inhibi-
tors (NS1 and L-NAME) aimed at the reductase and ox-
ygenase domains, respectively. It has been established 
that two compounds that have one carboxymethyl 
group at the 3’-position of the ribose colocalize with 
the help of the Golgi apparatus (the main intracellular 
location of eNOS) and demonstrate a high intracellu-
lar two-photon brightness. In addition, eNOS-depend-
ent photo-oxidation was observed only for these two 
compounds, which is accompanied by a significant in-
tracellular production of NO, which takes into account 
specific photo-cytotoxic effects. Thus, it is obvious that 
effective photoactivatable NADPH analogues targeting 
NOS can have important consequences for the gener-
ation of apoptosis in tumor cells or the modulation of 
NO-dependent physiological processes. Studies have 
also shown a role of a number of naturally occurring 
phenolic compounds, such as berberine, timoquinone, 
catechin, celastrol, apocynin, resveratrol, curcumin, 
hesperidin, G-hesperidin and quercetin in the inhibition 
of NOX (Yousefian et al. 2019).
NOX1 and NOX2 oxidases appear to be the main 
causes of vascular oxidative stress in cardiovascular 
diseases, which makes them promising targets; howev-
er, a rational development of highly selective inhibitors 
of these isoforms is required. NOX2 oxidase plays a 
decisive role in oxidative stress and vascular dysfunc-
tion caused by insulin resistance (Sukumar et al. 2013). 
Acute and chronic inhibition of NOX2 with the 18-ami-
no acid peptide gp91ds-tat causes the restoration of 
vasomotor function and a decrease in oxidative stress 
in animal models of insulin resistance (Sukumar et al. 
2013). In transgenic mice with endothelium insulin re-
sistance and the deleted NOX2 genome, superoxide 
anion formation reduced and the vascular function im-
proved, which also indicates the involvement of NOX2 
oxidase in the pathogenesis of diabetic endothelial dys-
function (Sukumar et al. 2013). The activation of NOX2 
oxidase was documented and confirmed in neurovascu-
lar endothelium and neurons in such neurodegenerative 
diseases,as mild cognitive impairment, Parkinsons dis-
ease, and Alzheimer’s disease (Zhang et al. 2001). The 
survival rate of neurons is significantly reduced in the 
presence of β-amyloid, but the toxic effect of the lat-
ter is weakened in the presence of apocynin, which is 
a NOX2 inhibitor (Cahill-Smith and Li 2014). NADPH 
oxidases are also considered as therapeutic targets for 
new treatments for ischemic stroke, often accompanied 
by endothelial dysfunction of cerebral vessels (McCann 
and Roulston 2013). Such inhibitors of NOX2 oxidase, 
such as apocynin, diphenylene iodonium, gp91ds-tat, 
VAS2870 (Table 1) showed promising results in reduc-
ing damage and restoring ischemia-exposed laboratory 
animals (McCann and Roulston 2013).
The role of ACE2 in the 
pharmacological correction of 
endothelial dysfunction
The next molecular target, the pharmacological effect on 
which can lead to an improvement in endothelial dysfunc-
tion, is agiotensin-converting enzyme 2 (ACE2). ACE2 
catalyzes the transformation of peptides Ang I and Ang II 
into shorter peptides Ang-(1–9) and Ang-(1–7).
Numerous data suggest that the renin-angiotensin 
system (RAS) is the most important regulator of cardi-
ovascular homeostasis and plays an important role in the 
pathogenesis of endothelial dysfunction and atherosclero-
sis (Zhang et al. 2015).
The low content of Ang-(1–7), caused by deactivation 
of ACE2, leads to vascular damage in hypertension, dia-
betes, atherosclerosis and kidney disease (Montezano et 
al. 2014). The effect of the low-molecular-weight com-
pound XNT, which activates ACE2, on the endothelial 
function was studied in spontaneously hypertensive and 
diabetic rats (Fraga-Silva et al. 2013). The vasodilator 
responses of the aorta of the laboratory animals to acetyl-
choline and sodium nitroprusside increased significantly 
in XNT-treated (1 mg/kg per day for 4 weeks) animals 
with both pathologies; also a decrease in the level of ROS 
in the aorta was recorded (Fraga-Silva et al. 2013).
Currently, it has been demonstrated that overexpres-
sion of ACE2 and Ang-(1–7) protects the function of en-
dothelial cells and inhibits atherosclerotic evolution. The 
mechanism of protection of endothelial cells and the an-
ti-atherosclerotic action of ACE2 and Ang-(1–7) is due to 
the counterregulation of Ang II signaling, the inhibition of 
the inflammatory response and an increase in the ability 
of the antioxidant (Zhang et al. 2015).
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Table 1. Clinical studies of drugs that resulted in improved endothelial dysfunction.
Pathological 
condition Medicinal product Structural formula
Main pharmacological 
effects
Chronic heart failure Rosuvastatin (lipid-lowering drug of IV 
generation from the group of statins)
Oxidized LDL ↓
Lipid peroxidation ↓
Stem cells and progenitor 
cells ↑
POR ↑ (Erbs et al. 2011)
EDVD ↑
Apoptosis ↓
SOD ↑
MDA ↓
(Geng et al. 2019, 
Radenković et al. 2013)
Acute coronary 
syndrome
Perindopril (angiotensin converting enzyme 
(ACE) inhibitor)
Apoptosis ↓
CD34 + mobilization ↑
VEGF ↑
TNF-α ↓
Bradykinin ↑
Angiotensin 2 ↓
eNOS mRNA ↑
(Cangiano et al. 2011)
Cardiac syndrome X Nebivolol (cardioselective beta-blocker of 
III generation with vasodilating properties)
FMD ↔
High sensitivity to 
C-reactive protein ↓
Factor von Willebrand ↓
Fibrinogen ↓
MDA ↓
EDVD ↑
(Borghi et al. 2017)
Hypertensive 
left ventricular 
hypertrophy
Carvedilol (alpha and beta-blocker without 
internal sympathomimetic activity)
FMD ↑
Endothelin-1 ↓
NO ↑
(Xiaozhen et al. 2010)
ENVD ↑
(Peller et al. 2015)
Coronary heart disease 
and impaired glucose 
tolerance
Pioglitazone (selective stimulant of PPAR-γ 
receptors and, to a lesser extent, of PPAR-α 
receptors)
FMD ↑
TNF-α ↓
Triglycerides ↓
high molecular weight 
adiponectin ↑
(Rizza et al. 2011)
Hypertension and 
impaired glucose 
tolerance / Peripheral 
artery disease
Telmisartan (angiotensin II receptor 
antagonist)
FMD ↑
Insulin resistance ↓
Glucose Tolerance ↑
(Perl et al. 2010)
P38 MAPK
NO ↑
Angiotensin 2 ↓
(Radenković et al. 2013)
Maximum walking distance 
↑
FMD ↑
(Zankl et al. 2010)
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Pathological 
condition Medicinal product Structural formula
Main pharmacological 
effects
Type 2 diabetes Gliclazide (insulin secretion stimulator by 
pancreatic beta cells)
FMD ↑
Endothelial progenitor 
cells ↑
(Chen et al. 2011)
IL-6 ↓
ICAM-1 ↓
E-selectin ↓
(Erem et al. 2014)
Obesity Pitavastatin (HMG-CoA reductase 
inhibitor)
FMD ↑
Triglycerides ↑
(Nagashima and Endo 2011)
Apoptosis ↓
NO ↑
PGE2 ↓
eNOS ↑
(Haybar et al. 2019)
Behcet’s disease Atorvastatin (selective competitive 
inhibitor of HMG-CoA reductase)
Behcet’s disease Lisinopril (an ACE inhibitor of prolonged 
action)
FMD ↑
(Inanc et al. 2010)
Apoptosis ↓
CD34 + mobilization ↑
TNF-α ↓
Bradykinin ↑
Angiotensin 2 ↓
(Cangiano et al. 2010)
Polycystic ovary 
syndrome
Spironolactone (potassium-sparing diuretic, 
competitive antagonist of aldosterone and 
other mineralocorticoids)
FMD ↑
(Bajuk et al. 2011)
Icam-1
ROS ↓
eNOS ↑
(Dutzmann et al. 2014)
Subclinical 
hypothyroidism
Levothyroxine POR ↑
FT4 ↑
TSH ↓
Total cholesterol ↓
Ankylosing spondylitis Infliximab (monoclonal antibodies to 
TNF-α)
−
FMD ↑
Serum nitrite ↓
Erythrocyte sedimentation 
rate ↓
C-reactive protein ↓
(Syngle et al. 2010)
Chronic hemodialysis Simvastatin (active metabolite inhibits 
HMG-CoA reductase)
FMD ↑
Oxidized LDL ↓
VCAM-1 ↓
8-epi-prostagandin F2 ↓
NO bioavailability
(Kishimoto et al. 2019)
Note: LDL − low-density lipoproteins; SOD − superoxide dismutase; MDA − malonic dialdehyde; FMD − flow-mediated dilatation; VEGF – Vas-
cular endothelial growth factor; TNF-α − tumor necrosis factor –α; TSH − thyroid-stimulating hormone; VCAM-1 − vascular cell adhesion molecule 
1; ROS – reactive oxygen species; eNOS – endothelial nitric oxide synthase.
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Table 2. NADPH inhibitors•H-oxidases (26).
Name Structural formula Mechanism of action related to NADP•H-oxidase
Other pharmacolo-
gical effects
4- (2-aminoethyl) 
benzenesulfonylfluoride
S
O
O
F
NH2
HCl Oxidase assembly inhibitor: inhibits the association of the NOX2 subunit and p47phox. 
Does not remove O2•- generated in systems that 
do not contain cells
Non-selective serine 
protease inhibitor
Apocynin O
OH
OCH3
Oxidase assembly inhibitor: inhibits the 
association of p47phox and membrane-bound 
heterodimer
H2O2 absorber
Diphenyleneiodonium I+ Flavoprotein inhibitor Inhibitor of NADPH•H-ubiquinone 
oxidoreductase, 
NADPH 
•H-dehydrogenase, 
xanthine oxidase, 
cytochrome-p450 
oxidoreductase, NOS 
and bacterial nicotine 
oxidase
GK-136901
N
N
H
N
O
O
N
The claimed inhibitor of NOX1 and NOX4 
oxidases. The mechanism of action is not 
established, but the structural similarity with 
NADP•H implies competitive substrate inhibition
−
ML171
S
H
N
O Selective inhibitor of NOX1 oxidase (IC50 0.25 
μM) compared with other isoforms of NADPH-H 
oxidases (IC
50
>3 μM). Does not absorb ROS 
generated by xanthine oxidase
−
Nox2ds-tat (H)-RKKRRQRRRCSTRIRRQL-NH2 Oxidase assembly inhibitor: inhibits the 
association of the NOX2 subunit and p47phox. 
Does not remove O2•- generated in systems that 
do not contain cells
−
Plumbagin O
OOH
Inhibits the NADPH-dependent O2•- formation 
in various cell lines expressing NOX4 oxidase; 
mechanism of action is unknown
Chemical structure 
can provide an ROS-
absorbing effect.
PR-39 RRRPRPPYLPRPRPPPFFPPRLPPRIPPG
FPPRFPPRFP
Binds to the SH3 domains of the p47phox 
subunit and prevents binding to the p22phox 
subunit
Appears to bind 
to other proteins 
containing SH3 
domains.
S17834
OHO
OH O
OH
OCH3
Alleged direct inhibitor of NADPH oxidase, but 
the mechanism of action is not established.
−
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Name Structural formula Mechanism of action related to NADP•H-oxidase
Other pharmacolo-
gical effects
VAS2870
N
O
S
N
N
N
NN
Unidentified action mechanism, does not bind 
O2•-
−
VAS3947
N
O
S
N
N
N
NN
Reduces ROS produced by NADPH-oxidase, has 
micromolar activity, regardless of the isoform, 
does not inhibit the formation of ROS by 
xanthine oxidase and eNOS activity
−
Note: eNOS – endothelial NO synthase; SH3 – Src homologous 3 domain.
Arginase II is a promising target 
for the creation of drugs aimed at 
the pharmacological correction of 
endothelium-associated pathology
The decrease in the bioavailability of NO, leading to en-
dothelial dysfunction, can be caused by competition bet-
ween endothelial NO synthase (eNOS) and arginase for a 
common substrate – L-arginine. The expression of argi-
nase and its activity is increased in many cardiovascular 
diseases, including ischemic-reperfusion injuries, hyper-
tension, atherosclerosis, and diabetes (Rabelo et al. 2015, 
Shakhno et al. 2017).
The studies conducted have provided evidence of the 
role of Arg-I in promoting endothelial cell aging, confirm-
ing that activation of both Arg-I and Arg-II have similar 
functions of inducing the uncoupling of eNOS from the 
substrate. The molecular basis for the existing subtle differ-
ence between Arg-I and Arg-II is yet to be further studied.
Arginase contributes to microvascular endothelial dys-
function in obesity. Its effect decreases with age due to a 
higher level of vascular oxidative stress. Obesity is ac-
companied by accelerated microvascular remodeling, the 
extent of which is related to the amount of arginase in the 
vascular wall (Masi et al. 2018).
In endothelial cells, arginase isoform II prevails. The 
structure of both human arginase isoforms was studied 
using an X-ray structural analysis, which made it possi-
ble to identify a binuclear manganese cluster in the active 
site of enzymes and the identical structure of the active 
sites. In the active site of the enzyme, ornithine and urea 
are formed as a result of the breakdown of the tetrahe-
dral intermediate formed by adding a hydroxide anion 
coordinated by manganese ions to the guanidine group of 
arginine. The breakthrough step in the development of ar-
ginase inhibitors was the discovery of 2-(S)-amino-6-bo-
ronohexanoic acid (ABH) (Masi et al. 2018). A fragment 
of boronic acid ABH undergoes a nucleophilic attack by 
a hydroxide anion, as a result of which a tetrahedral bo-
ronate anion is formed, resembling an intermediate, re-
sulting in the cleavage of arginine. The rational design of 
stronger inhibitors led to the understanding that substit-
uents can be introduced into the α-position of the amino 
acid fragment, providing for additional interactions with 
arginase. The result of this work was the production of 
(R)-2-amino-6-borono-2-(2-(piperidin-1-yl) ethyl) hexa-
noic acid (1) (Fig. 1), which has sub-micromolar activ-
ity with respect to human arginase I and II (Van Zandt et 
al. 2013). Inhibitor 1 was also investigated in the in vivo 
model of myocardial ischemia / reperfusion injury and 
showed a significant reduction in the area of infarction 
(Van Zandt et al. 2013). It should be noted that the enan-
tiomer of compound 1, which is distinguished by the ab-
solute configuration of the stereogenic center, has neither 
an inhibitory activity against arginase, nor a therapeutic 
effect in myocardial ischemia.
The introduction of the piperidine and tropan frag-
ments into the α-position of the ABH amino acid fragment 
resulted in arginase inhibitors 2 and 3, respectively (Fig. 
1), having a nanomolar activity against human arginase 
(Golebiowski et al. 2013). Correction of endothelial dys-
function caused by obesity was achieved by introduc-
ing the inhibitor of arginase Nω-hydroxy-nor-L-arginine 
(nor-NOHA) into the diet of the studied rats (Chung et al. 
2014). In this case, a significant increase in the expression 
of eNOS and in the level of NO and a significant decrease 
in the content of the intercellular adhesion molecule 1 
(ICAM-1) in plasma were recorded (Chung et al. 2014). 
Despite the curative effects of arginase inhibitors, its pres-
ence in macrophages should be taken into account, as it 
may entail inflammatory and other undesirable effects on 
the vessels and some organs (Steppan et al. 2013).
The possible role of the regulatory 
enzyme GSNO reductase 
(GSNOR) in the pharmacological 
correction of endothelial 
dysfunction
One of the main organs dependent on GSNOR is the heart 
and its surrounding vascular system. GSNOR is an attractive 
therapeutic goal. Inhibition of GSNOR increases the availa-
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bility of NO in the cell and, in turn, normalizes NO-media-
ted signaling pathways. (Cahill-Smith and Li 2014)
One of the physiological forms of NO is S-nitrosoglu-
tathione (GSNO) of cytoplasm. GSNO catabolism with 
the help of the GSNO reductase regulatory enzyme 
(GSNOR) reduces the amount of GSNO in vivo, which 
leads to an influence on the processes involving NO, 
including vasodilatation. The endothelial function was 
studied under the conditions of inhibiting GSNOR, and 
the vasodilating effect of the GSNOR inhibitor N6338 
was established (Chen et al. 2014). In hypertensive rats, 
oral administration of N6338 for 14 days reduced blood 
pressure and vascular resistance index, and restored the 
initially impaired flow-mediated vasodilation to the level 
of the normal animals. There was no chemical formula of 
N6338 in either (Chen et al. 2014), or in cross references.
In addition, dozens of small molecules were identified 
that can inhibit GSNOR to varying degrees (Green et al. 
2012, Jiang et al. 2016).
Two of them, N6022 (3-(5-(4-(1H-imidazol-1-yl) phe-
nyl)-1-(4-carbamoyl-2-methylphenyl)-1H-pyrrol-2-yl) 
propionic acid) and N91115 from Nivalis Therapeutics 
(USA) are promising as potentially safe and effective 
GSNOR inhibitors that have been clinically tested for the 
treatment of asthma (clinictrials.gov – NCT01316315) 
and cystic fibrosis. In mice, it has been demonstrated that 
the ILD compound SPL-334 functions as a prophylactic 
and therapeutic agent for attenuating profibrotic cytokines 
and the accumulation of collagen in the lungs.
Thus, GSNOR can also be considered as a target for 
drugs that improve endothelial dysfunction.
Conclusion
From an enzymological point of view, NOS has a number 
of unique properties: NOS is the most regulated enzyme 
in biology. This is the only known enzyme that has 5 co-
factors. As a result, the system, the generation of nitric 
oxide is the most sensitive system that responds to many 
changes that occur in the body.
The most recent studies showing the ubiquitous local-
ization of arginase I and II make it possible not to dwell 
on this differentiation and not to mark any significant dis-
tinction between selective and non-selective inhibitors. In 
addition, all arginase inhibitors are divided into specific, 
acting directly on the enzyme itself and blocking its active 
center, and non-specific, acting on the enzyme indirectly.
NOX1 and NOX2 oxidases, as NADP•H oxidase iso-
forms, expressed by endothelial cells, agiotensin-convert-
ing enzyme 2 and GSNO reductase may be of interest in a 
targeted search for drugs for the pharmacological correc-
tion of endothelial dysfunction.
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